Mechanisms of immunotherapy resistance in mCRPC: identifying the enemy on the visceral metastatic battlefield
Kim, J.W.; Bilusic, M.; Plimack, E.R.
Oncology 28(11): 986-990
2014
ISSN/ISBN: 0890-9091 PMID: 25403631 Document Number: 678035
Document emailed within 1 workday
Related Documents
Poulter, L.W.; Pearce, M.T. 1980: Mechanisms of immunity to leishmaniasis III. the development and decay of resistance during metastatic disease Clinical and Experimental Immunology 42(2): 211-218Négrier, S.; Mercatello, A.; Coronel, B.; Merrouche, Y.; Bret, M.; Blay, J.Y.; Thiesse, P.; Clavel, M.; Moskovtchenko, J.F.; Philip, T. 1993: Immunotherapy of metastatic kidney cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 3(2): 187-194
Lüftner, D.; Pollmann, D.; Schildhauer, S.; Sehouli, J.; Possinger, K. 2005: Perspectives of immunotherapy in metastatic breast cancer Anticancer Research 25(6c): 4599-4604
Akhtar, M.; Jazayeri, M.; Sra, J. 1991: Cardiovascular causes of syncope. Identifying and controlling trigger mechanisms Postgraduate Medicine 90(2): 87-94
Díaz, P.C.; Alvarez Gavilán, Y.; de Armas Rodríguez, Y.; Bisset Lazcano, J.A. 2007: Determination of insecticide-resistance and resistance mechanisms of Blattella germanica (Dictyoptera: Blattellidae) Revista Cubana de Medicina Tropical 59(2): 159-165
Sun, H.; Maglio, D.; Nicolau, D. 2004: Macrolide resistance in Streptococcus pneumoniae: mechanisms, patterns, and clinical implications of resistance Connecticut Medicine 68(9): 571-576
Mathé, G.; de Vassal, F.; Schwarzenberg, L.; Delgado, M.; Pena-Angulo, J.; Belpomme, D.; Pouillart, P.; Machover, D.; Misset, J.L.; Pico, J.L.; Weiner, R.; Jasmin, C.; Hayat, M.; Schneider, M.; Cattan, A.; Amiel, J.L.; Musset, M.; Rosenfeld, C. 1977: Acute lymphatic leukemia in children: results of ICIG-ALL protocols 9 and 10, involving respectively short and long chemotherapy before immunotherapy. Identifying two groups of patients according to prognostics La Nouvelle Presse Medicale 6(27): 2401-2407
Kraje, A.C.; Mears, E.A.; Hahn, K.A.; McEntee, M.F.; Mitchell, S.K. 1999: Unusual metastatic behavior and clinicopathologic findings in eight cats with cutaneous or visceral hemangiosarcoma Journal of the American Veterinary Medical Association 214(5): 670-672
Sibert, L.; Planet, M.; Kuhn, J.M.; Annoot, M.; Boillot, B.; Grise, P. 1994: Hypothyroidism and immunotherapy using interferon or interleukin for metastatic renal adenocarcinoma Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 4(4): 582-587
Dagnone, A.. J.; Young, I.D..; Morales, A. 1999: Metastatic renal cell carcinoma regression after nephrectomy and BCG immunotherapy Canadian Journal of Urology 6(2): 749-750
Courcambeck, J.ér.ôm.; Bouzidi, M.; Perbost, R.ég.; Jouirou, B.; Amrani, N.; Cacoub, P.; Pèpe, G.ér.; Sabatier, J.-M.; Halfon, P. 2006: Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations Antiviral Therapy 11(7): 847-855
Brinkmann, O.A.; Bruns, F.; Prott, F.J.; Hertle, L. 1999: Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC) Anticancer Research 19(2c): 1583-1587
Bourlon, M.ía.T.; Velázquez, H.E.; Luna-Santiago, R.; Vázquez-Manjarrez, S.; Bourlon, C. 2018: Is this Patient with Metastatic Bladder Cancer a Candidate for Second-Line Immunotherapy Treatment? Oncology 32(2): 64-68
Negrier, S.; Douillard, J.-Y.; Gomez, F.éd.ér.; Lasset, C.; Chevreau, C.; Escudier, B. 2002: Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 12(2): 213-218
Kan, N.; Imamura, M. 1993: Loco-regional immunotherapy with OK-432 and cultured autologous lymphocytes for patients with metastatic cancer Human Cell 6(2): 100-105
Yu, S.S.; Dorff, T.B.; Ballas, L.K.; Sadeghi, S.; Skinner, E.C.; Quinn, D.I. 2017: Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease Clinical Advances in Hematology and Oncology: H&o 15(6): 466-477
Stathopoulos, G.P.; Baxevanis, C.N.; Papadopoulos, N.G.; Zarkadis, I.K.; Papacostas, P.; Michailakis, E.; Tsiatas, M.L.; Papamichail, M. 1996: Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters Anticancer Research 16(6b): 3855-3860
Poriadin, G.V.; Salmasi, Z.M.; Makarkov, A.I. 1998: Lymphocyte apoptosis--one of mechanisms of specific immunotherapy of atopic diseases Biulleten' Eksperimental'noi Biologii i Meditsiny 125(4): 434-436
Wenisch, H.J.; Markus, B.H.; Herrmann, G.H.; Usadel, K.H.; Encke, A. 1992: Multi-visceral upper abdominal resection and orthotopic liver transplantation--a surgical treatment concept for regionally metastatic tumors of the endocrine pancreas Zentralblatt für Chirurgie 117(6): 334-342
Gokin, A.P.; Kostyuk, P.G.; Preobrazhensky, N.N. 1977: Neuronal mechanisms of interactions of high-threshold visceral and somatic afferent influences in spinal cord and medulla Journal de Physiologie 73(3): 319-333